Disruption of HER2–HER3 dimerization is very important for HER2-driven signalling and is also qualified efficiently by pertuzumab132. The optimistic results from pertuzumab trials supported a method of targeting HER3, that has a vital function in HER2-mediated tumorigenesis. HER3 is unique when compared with other HER relatives as it can be https://www.directivepublications.org/journal-of-clinical-breast-cancer/